SecBot SecBot

PCRX drug pipeline

Pacira BioSciences, Inc. · 3 rated drugs
$36.48
+0.1% 1-day · Nov 16
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
±5.1%
1-day, median of 1 event
IV rank
21
IV 35% · HV 107%
Rated drugs
3
3 neutral
Phase 3 trials
3
1 with results posted

Upcoming catalysts

1 dated
  1. Dec 2026
    ZILRETTA
    Phase 3 primary completion

Drugs

soonest catalyst first
● neutral
Impact
PhaseApproved
Time to marketAlready approved and commercially marketed since 2011.

EXPAREL bupivacaine liposome injectable suspension Updated Nov 13

What to watch

EXPAREL is a mature, approved product with no upcoming binary drug catalyst. The stock trades at the $36.50 Viatris acquisition price, so the near-term move depends entirely on deal closing (expected by end of 2026). Watch for the Ninth Circuit royalty ruling's impact on EXPAREL margins and any updates on the tender offer's regulatory clearance.

Bull case
  • NOPAIN Act tailwind: Federal separate reimbursement for non-opioid pain management in outpatient settings creates a structural growth driver for EXPAREL.
  • Patent protection through 2030: Settlements with Fresenius, Jiangsu Hengrui, and eVenus (April 2025) pushed generic entry to 2030, extending the product's exclusivity runway.
  • Expanding label: FDA approved two additional nerve block indications in November 2023, broadening the addressable market.
Bear case
  • Generic competition: FDA approved Jiangsu Hengrui's generic bupivacaine liposome in July 2024, and while patent settlements push entry to 2030, further legal challenges could emerge.
  • Royalty dispute: On November 6, 2026, the Ninth Circuit reversed part of the lower court ruling, holding that Pacira owes royalties on EXPAREL made using its 200-liter process. This could pressure gross margins and put a $28.3M cash payment from RDF at risk.
  • Revenue erosion: Q3 2026 EXPAREL revenue was $176.65M, slightly down from $179M a year earlier, suggesting growth may be plateauing.
● neutral
Impact
PhasePhase 2 (not yet initiated)
Time to marketSeveral years away at minimum. The drug has not yet entered Phase 2 trials. Even if Phase 2 begins soon, the full clinical development path (Phase 2, Phase 3, regulatory filing) typically takes 4-7 years for a pain indication.

PCRX-2002 ropivacaine hydrogel Updated Oct 30

What to watch

The stock is trading at $36.39, essentially at Viatris's $36.50 tender offer price that expires November 16, 2026. The acquisition is the only relevant near-term catalyst for PCRX shares; PCRX-2002's Phase 2 initiation (expected later in 2026 per Q2 earnings) is a minor pipeline milestone at a company being acquired. Watch for any developments in the tender offer process or potential competing bids, though none have emerged since the October 8 announcement.

Bull case
  • PCRX-2002 addresses a large market: postsurgical pain management, where non-opioid alternatives are in high demand due to the opioid crisis.
  • Phase 1 data showed sustained ropivacaine release through 14 days, suggesting potential for extended pain relief from a single dose.
  • Patent protection extends to 2042, providing a long commercial runway if approved.
Bear case
  • PCRX-2002 is a very early-stage asset (Phase 2 not yet initiated) with no clinical efficacy data in patients yet; Phase 2 or later trials could fail.
  • Pacira is being acquired by Viatris for $36.50/share; the stock trades essentially at the offer price, so upside from pipeline progress is capped for current shareholders.
  • The postsurgical pain market is competitive, with multiple long-acting local anesthetics in development (e.g., HTX-011 from Heron Therapeutics).
● neutral
Impact
PhasePreclinical
Time to marketYears away, if ever. The program is still in preclinical (animal) testing, with a pilot efficacy study just initiating. Veterinary regulatory approval (USDA or equivalent) would follow successful studies, but no timeline has been disclosed.

PCRX-1001 Updated Oct 30

What to watch

PCRX-1001 has no dated binary catalyst. The stock is trading at $36.39, essentially at Viatris's $36.50/share tender offer price, so the acquisition outcome (expected to close by end of 2026) is the only material catalyst for PCRX shares. PCRX-1001's next milestone would be preclinical efficacy data or a potential out-licensing deal, neither of which is dated or would move the stock given the pending acquisition.

Bull case
  • Pacira has described PCRX-1001 as having significant out-licensing potential, meaning a partner could pay for rights to develop and commercialize the veterinary product.
  • The HCAd platform has already generated PCRX-201, a Phase 2 gene therapy for human knee OA, providing proof-of-concept for the technology.
  • Canine OA is a large veterinary market with growing demand for disease-modifying treatments beyond palliative care.
Bear case
  • PCRX-1001 is preclinical and unproven; no efficacy data in dogs has been reported yet.
  • The program is a veterinary product, which typically commands much lower commercial value than human therapeutics.
  • Pacira is being acquired by Viatris for $36.50/share, so PCRX-1001's standalone prospects have no bearing on the stock price; the acquisition price is already set.

Other drugs in filings and trials

no drug report yet

Past FDA events & how the stock moved

1 events
DateDrugEvent1 day5 days
Oct 6, 2017ZILRETTAApproval−5.1%−7.3%

Clinical trials

3 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
ZILRETTAZILRETTA in Subjects With Shoulder OsteoarthritisPhase 3Active not recruiting150Dec 2026
DuloxetineA Sequenced Strategy for Improving Outcomes in People With Knee Osteoarthritis PainPhase 3Completed1,937Apr 8, 2025
Liposomal bupivacaineThoracic Epidural Analgesia vs Surgical Site Infiltration With Liposomal Bupivacaine Following Open Gynecologic SurgeryPhase 3Completed · results106Mar 3, 2025